Creative Planning Increases Stock Holdings in Moderna, Inc. $MRNA

Creative Planning boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 19.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 107,593 shares of the company’s stock after acquiring an additional 17,519 shares during the quarter. Creative Planning’s holdings in Moderna were worth $2,969,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in MRNA. Geode Capital Management LLC grew its position in shares of Moderna by 19.1% in the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock valued at $244,458,000 after purchasing an additional 1,420,690 shares during the period. Invesco Ltd. raised its position in shares of Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after purchasing an additional 877,162 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Moderna by 0.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock valued at $101,982,000 after buying an additional 11,270 shares in the last quarter. Northern Trust Corp boosted its holdings in Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company’s stock worth $88,441,000 after buying an additional 160,572 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after buying an additional 285,662 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 6.1%

Shares of NASDAQ:MRNA opened at $23.72 on Monday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $48.92. The stock has a market cap of $9.27 billion, a P/E ratio of -2.94 and a beta of 2.02. The business has a fifty day moving average of $25.87 and a two-hundred day moving average of $26.98.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. During the same quarter in the previous year, the company posted $0.03 EPS. The company’s revenue was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Barclays reduced their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Morgan Stanley upped their target price on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. Finally, Leerink Partners raised their price target on shares of Moderna from $15.00 to $18.00 and gave the stock an “underperform” rating in a research note on Friday. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $29.46.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.